This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Private prescription with self-payment is legal across the EU and is the common route where public reimbursement is not available.
Reimbursement varies substantially by member state. Some (Germany, France, Netherlands) restrict weight-management coverage. Others are more permissive. That variation is the single most determinative factor in access for most EU residents.
Worth separating two things that post #29 runs together.
Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.
The correction was fair and I had been repeating something I had not checked carefully enough.
post #33 is right about the mechanism and I think understates the practical bit.
Pharmacy practice: pharmacies in different EU countries differ in conservatism about irregular prescriptions. Some will decline a prescription they consider irregular; others will not. Local pharmacy culture matters.
Coming back to post #33, because the follow-up matters more than the original answer.
Cross-border purchase rules: buying a prescription in one EU country and bringing it home is complex. The substance is legal but crossing borders with it requires understanding both countries' import rules.
France: ANSM implements EU framework. Reimbursement has been narrower for weight management. Prescribing restrictions were applied during shortages, directing available product toward diabetes indications.
post #37 answers the question as asked. The question underneath it is different.
Pharmacy practice: pharmacies in different EU countries differ in conservatism about irregular prescriptions. Some will decline a prescription they consider irregular; others will not. Local pharmacy culture matters.
I read post #37 twice before replying, because I had assumed the opposite.
EMA is the regulator with national implementation. Licensed incretin analogues are prescription-only across the EU, with some variation in specific approvals by member state.
This follows post #37 rather than contradicting it.
Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.
Coming back to post #40, because the follow-up matters more than the original answer.
Two things before anyone answers the substance.
First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.
post #42 answers the question as asked. The question underneath it is different.
France: ANSM implements EU framework. Reimbursement has been narrower for weight management. Prescribing restrictions were applied during shortages, directing available product toward diabetes indications.
Germany: BfArM implements EU framework. Statutory insurance (the majority) excludes "lifestyle medicines" including weight management. Private prescription is common. Private insurance sometimes covers it.
This follows post #42 rather than contradicting it.
Spain: AEMPS is the regulator. Public reimbursement for weight management has been limited with regional variation in specialist pathways. Private prescription is common.
I read post #44 twice before replying, because I had assumed the opposite.
Italy: AIFA controls reimbursement through a note system. Weight-management indications have not attracted public reimbursement. Regional health authorities add further variation.
Private prescription with self-payment is legal across the EU and is the common route where public reimbursement is not available.
Picking up post #46: that is the part I would want checked first.
Reimbursement varies substantially by member state. Some (Germany, France, Netherlands) restrict weight-management coverage. Others are more permissive. That variation is the single most determinative factor in access for most EU residents.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
[2026 update] EU-wide position versus national implementation
On the subject in the title: EU-wide position versus national implementation Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As of…
|
2 | 54k | 19mo | |
|
EMA product information as a primary source
Posting this under the heading it deserves: EMA product information as a primary source Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this category…
|
+70 | 74 | 7k | 8mo |
|
EMA product information as a primary source — does this still hold?
The question in the title: EMA product information as a primary source — does this still hold? I will give what I have already checked below so nobody repeats it. Documenting an access outcome, dated, because…
|
+127 | 150 | 41k | 20mo |
|
Revisiting: German, French and Dutch differences, compared
Posting this under the heading it deserves: Revisiting: German, French and Dutch differences, compared Everything below is what sits behind that. A coverage question with the paperwork detail included, since…
|
+90 | 99 | 32k | 9mo |
|
About the European Union category
EMA positions, national differences within the EU, and cross-border purchase rules. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…
|
+1 | 5 | 18k | 10mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Coming back to: Cross-border purchase rules within the EU
Cross-border purchase rules within the EU Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is what…
|
+12 | 16 | 2.8k | 11mo |
|
Prior authorisation: what the criteria usually require
On the subject in the title: Prior authorisation: what the criteria usually require Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is what…
|
+9 | 13 | 3.2k | 17mo |
|
Prescription requirements and telehealth models — a second dataset
On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. A logistics question, since the answers here are usually better than…
|
+87 | 94 | 1.1k | 21d |
|
[2026 update] Availability by country, dated, with primary sources
On the subject in the title: Availability by country, dated, with primary sources Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As…
|
+40 | 45 | 14k | 4mo |
|
What changed in 2026, by region
What changed in 2026, by region — that is the question, and I have not found it answered plainly anywhere I have looked. Documenting an access outcome, dated, because everything in this category expires. As…
|
+110 | 122 | 1.4k | 18mo |